Nasdaq Edges Higher; Crude Oil Falls Sharply U.S. stocks pared some losses midway through trading, with the Nasdaq Composite turning higher on Thursday. Benzinga · Aug 4, 2022
Dow Drops Over 100 Points; U.S. Trade Deficit Shrinks To This Level In June U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Thursday. Benzinga · Aug 4, 2022
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate Here's a roundup of top developments in the biotech space over the last 24 hours: Benzinga · Aug 4, 2022
Benzinga Before The Bell: Alibaba's Delisting Concerns, Amgen's Potential $10.7B Tax Bill, Kenya Will Not Shut Facebook Services And Other Top Financial Stories Monday, August 1 CNBC Benzinga · Aug 1, 2022
Amgen Whale Trades For July 12 Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Jul 12, 2022
Amgen is Our Growth Stock of the Week… Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week. StockNews.com · Jul 8, 2022
Check Out What Whales Are Doing With AMGN Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Jul 8, 2022
Peering Into Amgen's Recent Short Interest Amgen's (NASDAQ:AMGN) short percent of float has risen 7.63% since its last report. The company recently reported that it has 20.30 million shares sold short, which is 3.81% of all regular shares that are available for trading. Benzinga · Jun 27, 2022
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 10.41%. Currently, Amgen has a market capitalization of $130.40 billion. Benzinga · Jun 24, 2022
How Is The Market Feeling About Amgen? Amgen's (NASDAQ:AMGN) short percent of float has fallen 5.35% since its last report. The company recently reported that it has 18.85 million shares sold short, which is 3.54% of all regular shares that are available for trading. Benzinga · Jun 9, 2022
$100 Invested In Amgen 20 Years Ago Would Be Worth This Much Today Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 2.03% on an annualized basis producing an average annual return of 9.14%. Currently, Amgen has a market capitalization of $131.14 billion. Benzinga · Jun 8, 2022
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.74% on an annualized basis producing an average annual return of 10.5%. Currently, Amgen has a market capitalization of $136.00 billion. Benzinga · May 27, 2022
Analyst Ratings for Amgen Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter: Benzinga · May 23, 2022
Peering Into Amgen's Recent Short Interest Amgen's (NASDAQ:AMGN) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 20.75 million shares sold short, which is 3.9% of all regular shares that are available for trading. Benzinga · May 18, 2022
StockNews.com · May 16, 2022 2 Buy-Rated Dow Jones Stocks to Add to Your Portfolio Now Investors’ concerns over a potential recession due to the Fed’s policy measures to control inflation wreaked havoc on the stock market over the past few weeks. However, the recovery of the major stock-market indexes in the last trading session indicates that the market could be leveling off. With the possibility…
Benzinga · May 11, 2022 Executives Sell More Than $220M Of 3 Stocks US stock futures traded higher on this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Benzinga · May 9, 2022 This Is What Whales Are Betting On Amgen A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 21 strange trades.
Benzinga · May 2, 2022 Analyzing Amgen's Short Interest Amgen's (NASDAQ:AMGN) short percent of float has fallen 7.95% since its last report. The company recently reported that it has 22.52 million shares sold short, which is 4.05% of all regular shares that are available for trading.
Benzinga · Apr 29, 2022 Here's How Much $100 Invested In Amgen 10 Years Ago Would Be Worth Today Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.67%. Currently, Amgen has a market capitalization of $124.75 billion.
Benzinga · Apr 28, 2022 Check Out What Whales Are Doing With AMGN A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 18 strange trades.
Benzinga · Apr 28, 2022 Piper Sandler Maintains Overweight Rating for Amgen: Here's What You Need To Know Piper Sandler has decided to maintain its Overweight rating of Amgen (NASDAQ:AMGN) and raise its price target from $255.00 to $260.00. Shares of Amgen are trading down 5.5% over the last 24 hours, at $235.12 per share. A move to $260.00 would account for a 10.58% increase from the current…
Benzinga · Apr 28, 2022 Amgen's Return On Capital Employed Insights Pulled from Benzinga Pro data, Amgen (NASDAQ:AMGN) posted Q1 earnings of $1.48 billion, an increase from Q4 of 22.27%. Sales dropped to $6.24 billion, a 8.88% decrease between quarters.
Benzinga · Apr 28, 2022 Where Amgen Stands With Analysts Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:
Benzinga · Apr 28, 2022 The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · Apr 28, 2022 Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.